title: [Management of venous thromboembolism: A 2015 update].
abstract: Deep venous thrombosis (DVT) and pulmonary embolism (PE) constitute venous thromboembolic disease (VTE). Venous thromboembolic disease is a common, serious, and multifactorial disease, the incidence of which increases with age. Risk factors, whether transient (surgery, plaster immobilization, bed rest/hospitalization) or chronic/persistent (age, cancer, clinical or biological thrombophilia, etc.), modulate the duration of treatment. In the absence of pathognomonic clinical sign or symptom, diagnostic management relies in the evaluation of the clinical pre-test probability followed by a laboratory or an imaging testing. So far, compression ultrasound and multidetector computed tomography angiography are the best diagnostic tests to make a positive diagnosis of DVT or PE, respectively. Anticoagulants at therapeutic dose for at least 3months constitute the cornerstone of VTE management. Availability of new direct oral anticoagulants, which have recently been shown to be as effective and as safe as vitamin K antagonist in clinical trials, should facilitate ambulatory management of VTE and favour extended treatments for individuals with unprovoked VTE or VTE provoked by a chronic/persistent risk factor.
authors.affiliation: Centre d'investigations cliniques, université Montpellier I, Inserm CIC-1001, CHU de Montpellier, 34000 Montpellier, France; Service de médecine vasculaire, département de médecine interne, CHU de Montpellier, 34000 Montpellier, France.
authors.forename: J-P
authors.initials: JP
authors.lastname: Galanaud
authors.affiliation: Service de médecine vasculaire, hôpital européen Georges-Pompidou, 75015 Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Messas
authors.affiliation: Service d'explorations cardio-vasculaires, CHU de Pointe-à-Pitre, 97159 Pointe-à-Pitre, France.
authors.forename: A
authors.initials: A
authors.lastname: Blanchet-Deverly
authors.affiliation: Centre d'investigations cliniques, université Montpellier I, Inserm CIC-1001, CHU de Montpellier, 34000 Montpellier, France; Service de médecine vasculaire, département de médecine interne, CHU de Montpellier, 34000 Montpellier, France.
authors.forename: I
authors.initials: I
authors.lastname: Quéré
authors.affiliation: Service de médecine vasculaire, CHU de Nancy, 54511 Nancy, France.
authors.forename: D
authors.initials: D
authors.lastname: Wahl
authors.affiliation: Service de médecine vasculaire, CHU de Grenoble, 38043 Grenoble, France; CNRS, TIMC-IMAG UMR 5525, Themas, université Grenoble Alpes, 38043 Grenoble, France. Electronic address: GPernod@chu-grenoble.fr.
authors.forename: G
authors.initials: G
authors.lastname: Pernod
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D005260:Female; D006760:Hospitalization; D006801:Humans; D015994:Incidence; D009369:Neoplasms / Q000150:complications; D010353:Patient Education as Topic; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000175:diagnosis / Q000628:therapy; D011379:Prognosis; D053828:Stockings, Compression; D016306:Vena Cava Filters; D054556:Venous Thromboembolism / Q000175:diagnosis* / Q000628:therapy*
chemical_list: D000925:Anticoagulants; D000933:Antifibrinolytic Agents
keywords: Anticoagulant; Deep vein thrombosis; Embolie pulmonaire; Epidemiology; Maladie thromboembolique veineuse; Pulmonary embolism; Thrombose veineuse profonde; Traitement anticoagulant; Venous thromboembolic disease; Épidémiologie